Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors

Elena María Vida Navas1, Alberto Martínez Lorca2, Aintzane Sancho Gutiérrez3

  • 1Medical Oncology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.

Summary

Salvage peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE offers a viable treatment option for advanced neuroendocrine tumors (NETs) progressing after initial therapies. Retreatment demonstrates efficacy and manageable toxicity in NET patients.

Related Concept Videos